您的位置：山东大学 -> 科技期刊社 -> 《山东大学学报（医学版）》

山东大学学报（医学版） ›› 2015, Vol. 53 ›› Issue (9): 71-79.doi: 10.6040/j.issn.1671-7554.0.2015.514

• 临床医学 • 上一篇    下一篇

中国人群中血清TK1对不同恶性肿瘤诊断价值的Meta分析

刘京生1, 刘桂华1, 杜昆1, 赵倩2, 翁韶波1, 赵学英1, 张喜庄1, 金讯波3   

  1. 1. 华北石油管理局总医院泌尿外科, 河北 任丘 062552;
    2. 华北石油管理局总医院药材科, 河北 任丘 062552;
    3. 山东大学附属省立医院泌尿微创中心, 山东 济南 250021
  • 收稿日期:2015-05-25 出版日期:2015-09-10 发布日期:2015-09-10
  • 通讯作者: 金讯波。E-mail:16365451@qq.com E-mail:16365451@qq.com
  • 基金资助:
    河北省卫生厅青年科技课题(20110653)

Serum TK1 for the diagnosis of cancer in Chinese patients: a Meta-analysis

LIU Jingsheng1, LIU Guihua1, DU Kun1, ZHAO Qian2, WENG Shaobo1, ZHAO Xueying1, ZHANG Xizhuang1, JIN Xunbo3   

  1. 1. Department of Urology, North China Petroleum Administration Bureau General Hospital, Renqiu 062552, Hebei, China;
    2. Department of Pharmacy, North China Petroleum Administration Bureau General Hospital, Renqiu 062552, Hebei, China;
    3. Department of Minimally Invasive Urology Center, Provincial Hospital Affiliated to Shandong University, Jinan 250021, Shandong, China
  • Received:2015-05-25 Online:2015-09-10 Published:2015-09-10
  • Contact: 金讯波。E-mail:16365451@qq.com E-mail:16365451@qq.com

PDF (PC)

323

摘要： 目的 系统评价核酸合成的关键酶——胸苷激酶1 (TK1) 在中国人群恶性肿瘤中的诊断价值。方法 在中国期刊全文数据库(CNKI)和万方数据库中检索2008年1月至2015年3月发表的相关临床研究,采用Revman 5.2和Meta Disc 1.4进行分析。结果 共检索到相关文献415篇,最终纳入45篇,包括2 976例肿瘤患者,并全部经“金标准”确诊。Meta分析结果显示,各亚组间均存在明显的异质性,血清TK1检测在中国人群不同类型恶性肿瘤中表现出中度敏感性,其中肺癌、乳腺癌、妇科恶性肿瘤、前列腺癌、胃癌、结直肠癌、食管癌亚组的合并诊断敏感性分别为0.508、0.638、0.524、0.656、0.583、0.546、0.681;相应诊断特异性分别为0.973、0.932、0.940、0.925、0.941、0.947、0.967。结论 血清TK1检测在中国人群不同类型恶性肿瘤的筛选及早期诊断中具有一定的临床应用价值,但尚不能单独作为肿瘤筛选和辅助的诊断标准。国内评估血清TK1诊断价值的诊断性试验质量不高,存在较大的异质性,需要更多高质量的研究进一步验证。

关键词: 敏感性, 胸苷激酶1, 癌症, Meta分析, 特异性

Abstract: Objective To evaluate significance of thymidine kinase 1 (TK1) detection in the diagnosis of malignant tumors in Chinese patients. Methods Clinical trials on TK1 detection published during Jan. 2008 to Mar 2015 were searched in databases of CNKI and Wan Fang. Revman 5.2 and Meta Disc 1.4 were used to perform the Meta-analysis.Results A total of 415 relevant articles were retrieved and 45 trials with 2,976 cancer patients (all diagnosed by the gold standard) were involved. Meta-analyses showed that the heterogeneity among studies was high, and the pooled Results suggested a moderate diagnostic efficacy. The sensitivities for lung cancer, breast cancer, gynecological cancer, prostatic cancer, gastric cancer, intestinal cancer and esophagus cancer were 0.508, 0.638, 0.524, 0.656, 0.583, 0.546, and 0.681, respectively. The specificities were 0.973, 0.932, 0.940, 0.925, 0.941, 0.947, and 0.967. Conclusion TK1 detection may have certain value in the early diagnosis and screening of malignant cancers, but it can not be serveed as an independent reference test. More high quality trials are required to confirm the significance of TK1 detection.

Key words: Thymidine kinase 1, Cancer, Specificity, Meta-analysis, Sensitivity

中图分类号: 

  • R730.4
[1] Aufderklamm S, Todenhöfer T, Gakis G, et al. Thymidine kinase and cancer monitoring[J]. Cancer Letters, 2012, 316(1):6-10.
[2] Chen YL, Eriksson S, Chang ZF. Regulation and functional contribution of thymidine kinase 1 in repair of DNA damage[J]. J Biol Chem, 2010, 285(35):27327-27335.
[3] Xu Y, Shi QL, Ma H, et al. High thymidine kinase 1 (TK1) expression is a predictor of poor survival in patients with pT1 of lung adenocarcinoma[J]. Tumour Biol, 2012, 33(2):475-483.
[4] Stalhandske P, Wang L, Westberg S, et al. Homogeneous assay for realtime and simultaneous detection of thymidine kinase 1 and deoxycytidine kinase activities[J]. Anal Biochem, 2013, 432(2):155-164.
[5] Xiang Y, Zeng H, Liu X, et al. Thymidine kinase 1 as a diagnostic tumor marker is of moderate value in cancer patients: A meta-analysis[J]. Biomed Rep, 2013, 1(4):629-637.
[6] 刘鹏飞, 姬舒荣.血清胸苷激酶1在恶性肿瘤筛查和复发转移监测中研究进展[J].中华临床医师杂志:电子版, 2013, 7(23):10858-10860. LIU Pengfei, JI Shurong. Progress advances on serum thymidine kinase 1 in screening and monitoring of malignant tumor recurrence and metastasis[J/CD]. Chin J Clinicians (Electronic Edition), 2013, 7(23):10858-10860.
[7] Chen YL, Eriksson S, Chang ZF. Regulation and functional contribution of thymidine kinase 1 in repair of DNA damage[J]. J Biol Chem, 2010, 285(35):27327-27335.
[8] Zhou J, He E, Skog S. The proliferation marker thymidine kinase 1 in clinical use[J]. Mol Clin Oncol, 2013, 1(1):18-28.
[9] Nisman B, Allweis T, Kaduri L, et al. Serum thymidine kinase 1 activity in breast cancer[J]. Cancer Biomark, 2010, 7(2):65-72.
[10] He E, Xu XH, Guan H, et al. Thymidine kinase 1 is a potential marker for prognosis and monitoring the response to treatment of patients with breast, lung, and esophageal cancer and non-Hodgkin's lymphoma[J]. Nucleosides Nucleotides Nucleic Acids, 2010, 29(4-6):352-358.
[11] Wu BJ, Li WP, Qian C, et al. Increased serum level of thymidine kinase 1 correlates with metastatic site in patients with malignant melanoma[J]. Tumour Biol, 2013, 34(2):643-648.
[12] 邹雄. 胸苷激酶1是恶性肿瘤预后判断的动态标志[J]. 实用检验医师杂志, 2013, 5(2):67-71. ZOU Xiong. Serum thymidine kinase 1 activity is a dynamic marker of the prognosis of malignant tumor[J]. Chinese Journal of Laboratory Pathologist, 2013, 5(2):67-71.
[13] 郭丽香, 刘树业. 胸苷激酶1—新型的细胞增殖动力学标志[J].哈尔滨医药, 2014(5):316-317. GUO Liuxiang, LIU Shuye. Thymidine kinase 1-a new cell proliferation marker[J]. Harbin Medical Journal, 2014(5):316-317.
[14] 徐文静, 刘德干. 血清胸苷激酶1与肿瘤[J]. 国际肿瘤学杂志, 2013, 40(9):643-645. XU Wenjing, LIU Degan. Serum thymidine kinase 1 and cancer[J]. Journal of International Oncology, 2013, 40(9):643-645.
[15] Chen G, He C, Li L, et al. Nuclear TK1 expression is an independent prognostic factor for survival in pre-malignant and malignant lesions of the cervix[J]. BMC Cancer, 2013, 13:249. doi: 10.1186/1471-2407-13-249.
[16] Chen Y, YingM, Chen Y, et al. Serum thymidine kinase 1 correlates to clinical stages and clinical reactions and monitors the outcome of therapy of 1,247 cancer patients in routine clinical settings[J]. Int J Clin Oncol, 2010, 15(4):359-368.
[17] Xu Y, Liu B, Shi QL, et al. Thymidine kinase 1 is a better prognostic marker than Ki-67 for pT1 adenocarcinoma of the lung[J]. Int J Clin Exp Med, 2014, 7(8):2120-2128.
[18] Chen ZH, Huang SQ, Wang Y, et al. Serological thymidine kinase 1 is a biomarker for early detection of tumors-A health screening study on 35,365 people, using a sensitive chemiluminescent dot blot assay[J]. Sensors, 2011, 11(12):11064-11080.
[19] Bolayirli M, Papila C, Korkmaz GG, et al. Serum thymidine kinase 1 activity in solid tumor (breast and colorectal cancer) patients treated with adjuvant chemotherapy[J]. J Clin Lab Anal, 2013, 27(3):220-226.
[20] Chen F, Tang L, Xia T, et al. Serum thymidine kinase 1 levels predict cancer-free survival following neoadjuvant, surgical and adjuvant treatment of patients with locally advanced breast cancer[J]. Mol Clin Oncol, 2013, 1(5):894-902.
[21] Huang ZH, Tian XS, Li R, et al. Elevated thymidine kinase 1 in serum following neoadjuvant chemotherapy predicts poor outcome for patients with locally advanced breast cancer[J]. Exp Ther Med, 2012, 3(2):331-335.
[1] 林萍珍,薛娇美,杨蓓,李萌,周麦琳,曹枫林. 基于Pearson相关系数的癌症患者创伤后成长与心理适应相关性的Meta分析[J]. 山东大学学报（医学版）, 2017, 55(9): 110-121.
[2] 殷雷,殷睿,李文佳,刘帅,吕家驹. CYLD抑制自噬提高膀胱癌细胞吉西他滨化疗敏感性[J]. 山东大学学报（医学版）, 2017, 55(8): 1-6.
[3] 郑瑾,张江伟,王旭珍,匡陪丹,何晓丽,薛武军. 肾移植术后早期淋巴细胞及DSA监测在诊断移植排斥反应中的意义[J]. 山东大学学报（医学版）, 2017, 55(7): 89-94.
[4] 杜金阁,陈慧,杨孝荣,吕明. STAT4 rs7574865位点单核苷酸多态性与系统性红斑狼疮易感性Meta分析[J]. 山东大学学报（医学版）, 2017, 55(5): 95-102.
[5] 蔡远楚,王家林,张军,姚能亮,孙晓杰. 山东省5县癌症幸存者工作状况及影响因素[J]. 山东大学学报（医学版）, 2017, 55(4): 96-100.
[6] 王丽丽,霍彬,王磊,汪浩,侯定坤,霍小东,王金焕,臧立,曹强,柴树德,王海涛. 亚肺叶切除联合125I粒子植入治疗早期肺癌有效性的Meta分析与系统评价[J]. 山东大学学报（医学版）, 2017, 55(10): 76-83.
[7] 徐闯,戚大春,李贤让,祖萌,李健,刘明廷. 初次髋关节置换术后引流与否的Meta分析[J]. 山东大学学报（医学版）, 2016, 54(6): 43-49.
[8] 于玉娟,高成杰,王晓鹏,李波. 帕瑞昔布钠对脑肿瘤切除术患者炎症反应的影响及脑保护作用[J]. 山东大学学报（医学版）, 2016, 54(6): 65-68.
[9] 臧丽娇,仇杰,庄根苗,安丽. 血清S100B蛋白、神经元特异性烯醇化酶与新生儿低血糖脑损伤的相关性[J]. 山东大学学报（医学版）, 2016, 54(4): 51-54.
[10] 王立敏,王旭东. 吸氧浓度对心肺复苏大鼠S100β蛋白和神经元特异性烯醇化酶表达的影响[J]. 山东大学学报（医学版）, 2016, 54(3): 5-8.
[11] 木哈达斯·吐尔逊依明,帕它木·莫合买提,托兰古丽·买买提库尔班. CDKAL1(rs10946398 C/A)基因多态性与2型糖尿病易感性关系Meta分析[J]. 山东大学学报（医学版）, 2016, 54(2): 75-85.
[12] 张志强,吴艳华,王茂水,王新锋,汪运山. 联合检测血清PCT和NSE对小细胞肺癌的诊断价值[J]. 山东大学学报（医学版）, 2016, 54(11): 36-39.
[13] 孙祥耀,海涌,张希诺. 经皮内固定术与传统后路开放内固定术治疗胸腰椎骨折不良事件比较的Meta分析[J]. 山东大学学报（医学版）, 2016, 54(11): 56-63.
[14] 孙昊,汪春娟,王戈,王宝洁,郭守刚. 视神经脊髓炎谱系疾病伴常见非器官特异性自身抗体的特点[J]. 山东大学学报（医学版）, 2016, 54(10): 50-54.
[15] 苏静, 薛娇美, 孙菲菲, 郭兆新, 程翔宇, 孟力维, 刘照旭. 肾单位保留术和肾癌根治术治疗T1b期肾癌的Meta分析[J]. 山东大学学报（医学版）, 2015, 53(9): 65-70.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
版权所有 © 2018 《山东大学学报(医学版)》编辑部　
地址:山东大学科技期刊社（济南市历城区山大南路27号山东大学中心校区明德楼B座721室） 电话: 0531-88366918 E-mail: xbyxb@sdu.edu.cn
本系统由北京玛格泰克科技发展有限公司设计开发